These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35545174)

  • 1. Associations Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC.
    Gross CP; Meyer CS; Ogale S; Kent M; Wong WB
    J Natl Compr Canc Netw; 2022 May; 20(5):479-487.e2. PubMed ID: 35545174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of Precision Medicine in Advanced Non-Small Cell Lung Cancer: Real-World Outcomes Associated with the Use of Companion Diagnostics.
    John A; Shah RA; Wong WB; Schneider CE; Alexander M
    Oncologist; 2020 Nov; 25(11):e1743-e1752. PubMed ID: 32627882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer.
    Wu N; Ge W; Quek RG; Gleeson M; Pouliot JF; Dietz H; Jalbert JJ; Harnett J; Antonia SJ
    Future Oncol; 2022 Dec; 18(39):4385-4397. PubMed ID: 36656547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in Use of Next-Generation Sequencing in Patients With Solid Tumors by Race and Ethnicity After Implementation of the Medicare National Coverage Determination.
    Sheinson DM; Wong WB; Meyer CS; Stergiopoulos S; Lofgren KT; Flores C; Adams DV; Fleury ME
    JAMA Netw Open; 2021 Dec; 4(12):e2138219. PubMed ID: 34882180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker Testing, Treatment, and Outcomes in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Using a Real-World Database.
    Bhandari NR; Hess LM; He D; Peterson P
    J Natl Compr Canc Netw; 2023 Sep; 21(9):934-944.e1. PubMed ID: 37673115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data.
    John A; Yang B; Shah R
    Adv Ther; 2021 Mar; 38(3):1552-1566. PubMed ID: 33537872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis, testing, treatment, and outcomes among patients with advanced non-small cell lung cancer in the United States.
    Yang M; MacEwan JP; Boppudi SS; McClain MR; O'Hara RM; Paik PK
    Cancer Med; 2023 Dec; 12(24):21605-21614. PubMed ID: 38062905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disparities in Systemic Treatment Use in Advanced-stage Non-Small Cell Lung Cancer by Source of Health Insurance.
    Maguire FB; Morris CR; Parikh-Patel A; Cress RD; Keegan THM; Li CS; Lin PS; Kizer KW
    Cancer Epidemiol Biomarkers Prev; 2019 Jun; 28(6):1059-1066. PubMed ID: 30842132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of insurance status on receipt of definitive surgical therapy and posttreatment outcomes in early stage lung cancer.
    Stokes SM; Wakeam E; Swords DS; Stringham JR; Varghese TK
    Surgery; 2018 Dec; 164(6):1287-1293. PubMed ID: 30170821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Medicare's National Coverage Determination and Utilization of Next-Generation Sequencing.
    Sheinson DM; Wong WB; Flores C; Ogale S; Gross CP
    JCO Oncol Pract; 2021 Nov; 17(11):e1774-e1784. PubMed ID: 34043456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
    Schwartzberg L; Daniel D; Vaena D; Slater D; Staszewski H; Fang B; Seneviratne L; Yu E; Price R; Szado T; Meyer CS; Shah A; Ma E
    Future Oncol; 2023 Jun; 19(20):1397-1414. PubMed ID: 37318757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy.
    Ramagopalan S; Leahy TP; Ray J; Wilkinson S; Sammon C; Subbiah V
    BMC Med; 2021 Sep; 19(1):209. PubMed ID: 34521405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Impact of Oncology Care Model Reporting Requirements on Biomarker Testing and Treatment.
    Castellanos EH; Orlando A; Ma X; Parikh RB; O'Connell G; Meropol NJ; Hamrick J; Adamson BJS
    JCO Oncol Pract; 2020 Oct; 16(10):e1216-e1221. PubMed ID: 32496874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Insurance Coverage Paradox - Characterizing Outcomes among Dual-Eligible Hemorrhagic Stroke Patients.
    Pierre-Louis YS; Perla KMR; Perez GM; Jean-Charles S; Tang O; Nwaiwu CA; Weil R; Shah NS; Heffernan DS; Moreira C;
    J Clin Neurosci; 2022 Mar; 97():99-105. PubMed ID: 35074583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma.
    Jain V; Venigalla S; Sebro RA; Karakousis GC; Wilson RJ; Weber KL; Shabason JE
    Cancer Med; 2019 Oct; 8(14):6295-6304. PubMed ID: 31483578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network.
    Robert NJ; Espirito JL; Chen L; Nwokeji E; Karhade M; Evangelist M; Spira A; Neubauer M; Bullock S; Walberg J; Cheng SK; Coleman RL
    Lung Cancer; 2022 Apr; 166():197-204. PubMed ID: 35313244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Low-Value Care in Medicaid vs Commercially Insured Populations.
    Charlesworth CJ; Meath TH; Schwartz AL; McConnell KJ
    JAMA Intern Med; 2016 Jul; 176(7):998-1004. PubMed ID: 27244044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors.
    Markt SC; Lago-Hernandez CA; Miller RE; Mahal BA; Bernard B; Albiges L; Frazier LA; Beard CJ; Wright AA; Sweeney CJ
    Cancer; 2016 Oct; 122(20):3127-3135. PubMed ID: 27500561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis.
    Halpern MT; Ward EM; Pavluck AL; Schrag NM; Bian J; Chen AY
    Lancet Oncol; 2008 Mar; 9(3):222-31. PubMed ID: 18282806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.